Ardelyx Q2 2026: IBSRELA Powers 31% Revenue Surge, Losses Narrow, and Cash Runway Extends
ARDX is trading near its 52-week low of $4.71 (4.5% below the low).
Summary
Ardelyx posted Q2 2026 revenue of $120.9M, up 24% year-over-year, driven by IBSRELA growth. Net loss narrowed to $16.7M. The company ended the quarter with $281.8M in cash and investments, and its CMS lawsuit was dismissed on appeal.
Key Events · Earnings and Guidance · ARDX
-
IBSRELA Drives 31% Product Revenue Growth
Product sales hit $118.1M in Q2 2026, up from $90.1M a year ago. IBSRELA led the charge with $86.2M (up 33%), while XPHOZAH contributed $31.9M (up 27%).
-
Net Loss Narrows to $16.7M
The Q2 2026 net loss came in at $16.7M, or $0.07 per share, compared to a $19.1M loss in Q2 2025. Operating expenses rose 19% to $133.3M, driven by higher R&D and commercial spending.
-
Cash Position Strengthened to $281.8M
Cash, equivalents, and short-term investments totaled $281.8M as of June 30, 2026, up from $264.7M at year-end 2025. A $50M Term F Loan was drawn on June 29, 2026, bringing total debt to $251.8M.
-
CMS Lawsuit Dismissed on Appeal
On June 26, 2026, the U.S. Court of Appeals affirmed the dismissal of Ardelyx's lawsuit against CMS regarding XPHOZAH's inclusion in the ESRD PPS. The company will not pursue further litigation, removing a legal overhang but confirming the loss of Medicare Part D coverage.
Analysis · ARDX · Life Sciences
A standout quarter for Ardelyx was fueled by IBSRELA, which jumped 33% to $86.2M and lifted total product revenue 31% to $118.1M. The net loss shrank to $16.7M from $19.1M a year ago, while cash and investments stood at $281.8M after a $50M term loan draw. The CMS lawsuit over XPHOZAH reimbursement was dismissed on appeal, removing a legal overhang but cementing the Medicare Part D coverage loss. Looking ahead, the Phase 3 CIC trial for IBSRELA is on track to complete enrollment by year-end, with data expected in the second half of 2027 — a key pipeline catalyst. Against a backdrop of recent insider selling and a stock trading near 52-week lows, these results show commercial momentum and a cash position sufficient to fund operations for at least a year.
At the time of this filing, ARDX was trading at $4.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.2B. The 52-week trading range was $4.71 to $8.40. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.